Updated:
Korea Bio Medical Science Institute
Korea Bio Medical Science Institute in Seoul is a hybrid biomedical research and investment entity focused on life-science ventures and AI-driven...
Korea Bio Medical Science Institute
The Korea Bio Medical Science Institute is a Seoul-based organization that occupies a hybrid position between a biomedical research body and an investment entity, leveraging capital to support life-science projects from lab bench to clinical application. Its founding details and wealth origin are not publicly documented, but its focus on bio-medical science funding aligns with South Korea's national push toward biotechnology and health-tech commercialization. Investment strategy centers on early-stage and translational ventures within biomedical science, digital health, and artificial-intelligence-driven diagnostics. The institute's portfolio includes backing for startups developing AI-based medical imaging and biomarker discovery platforms. Geographic activity is concentrated in South Korea, with potential cross-border collaborations into other Asian biomedical hubs such as Singapore and Japan. Deal structures appear to lean toward direct equity placements and research grants tied to intellectual property. Without a disclosed team size, AUM, or known principals, the institute's operational scale remains opaque. No LinkedIn or website content is available for verification. There are no publicly documented offices outside Seoul, nor adjacent philanthropic or operational vehicles. No recent operational events — such as fund closings or major deals — have been reported in the last 24 months in accessible English-language sources. The institute's structural differentiator is its integration of research as an asset class — funding internal and external biomedical science projects where the output is both scientific publication and commercializable IP. This model, common among Korean state-linked or university-affiliated entities, separates it from conventional family offices or venture firms.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Sector focus
Frequently asked questions
What is the Korea Bio Medical Science Institute's core investment focus?
The institute targets biomedical science and digital health, with emphasis on early-stage ventures in AI diagnostics, biomarker discovery, and translational medicine. Its model combines research funding with equity investment, often supporting projects from lab to clinical stage. Publicly available details on specific portfolio companies are limited.
How does the institute source deal flow?
Deal flow likely originates from in-house research programs, academic collaborations within South Korea's biomedical ecosystem, and partnerships with university labs or state-run research centers. The institute may also receive referrals from government-supported innovation agencies. Direct entrepreneurship programs or incubator affiliations are possible but unconfirmed.
Is Korea Bio Medical Science Institute a family office?
It is classified as 'other' due to the absence of disclosed ownership or wealth origin. Its structure — a biomedical research body with investment functions — does not fit the typical family-office model. It may operate as a government-linked entity, a university-affiliated foundation, or a private research foundation.
What investment stages does the institute target?
The institute appears to focus on early-stage and translational projects, from preclinical research through clinical validation and early commercialization. It may also provide follow-on funding for later-stage development. No public data confirms stage-specific allocation or typical cheque sizes.
Does the institute invest beyond South Korea?
Geographic focus is primarily South Korea. There is no public evidence of direct investments outside Asia, though collaborations with peers in Singapore or Japan are plausible given regional biomedical research networks. Expansion abroad, if it occurs, has not been formally disclosed.
Who leads investment decisions at the institute?
Named principals or an investment committee have not been publicly identified. Decision-making is likely overseen by scientific directors or a board drawn from academia and industry. No recent press releases or regulatory filings name a CEO, CIO, or managing director.
What is the institute's relationship with South Korea's government or universities?
Given the name and focus, the Korea Bio Medical Science Institute may be affiliated with a national research foundation, a university medical school, or a government-backed innovation cluster such as Seoul National University Hospital or the Korea Research Institute of Bioscience and Biotechnology. No direct link is publicly documented.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: